|
|
|
|
A randomized,prospective trial in 90 de novo parkinsonian patients showed that 4 years'treatment with lisuride resulted in significantly fewer end- of-dose disturbances and peak-dose dyskinesias,but also less improvement in parkinsonian disability,than with levodopa.Early combination of lisuride and a low dose of levodopa,during a 4-year follow-up,resulted in a therapeutic response equal to that achieved with high-dose levodopa alone,but significantly fewer end-of-dose failures and dyskinesias.Thus it seems advisable that treatment should begin in the early phase of the disease with a dopamine agonist such as lisuride combined with a low dose of levodopa. |
|